OR WAIT null SECS
Mourenx location will install new equipment, add hires in project as part of the France Relance recovery plan
Novasep, a supplier of services and technologies for the life sciences industry, has invested $7.3 million in its Mourenx site in France. Company officials say that this financial decision will not only modernize its active pharmaceutical ingredient (API) manufacturing facility, but will also strengthen its competitiveness in its respective markets.
The upgrade of this current good manufacturing practice (cGMP) center features new equipment and the revamping of clean rooms for API isolation. According to the company, this project will enhance Novasep’s flexibility and help develop capacity for the custom manufacturing of therapeutic molecules, in accordance with the highest quality and safety requirements and with improved environmental protection. Alongside the investment, Novasep will be creating seven openings at the Mourenx location.
This project was chosen as part of the France Relance recovery plan initiated by the French government; Novasep will be supported within the framework of the "Investissements d'Avenir" (Investments for the Future) program, which rewards innovative and promising industrial investments, to allow France to further its economic growth and employment potential.
Last month, for the oncology sector, the company increased its highly potent active pharmaceutical ingredients (HPAPIs) manufacturing capabilities on its Le Mans site, which is also located in France.